Anti-cancer Drugs

雜志介紹

Anti-cancer Drugs雜志介紹

《Anti-cancer Drugs》是一本以English為主的未開放獲取國際優秀期刊，中文名稱抗癌藥，本刊主要出版、報道醫學-ONCOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為1.8，最新CiteScore 指數為3.8。

本刊近期中國學者發表的論文主要有：

• MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating HSP90AA1

  Author: Zhou, Xiangqi; Zheng, Le; Zeng, Chunya; Wu, Yangjie; Tang, Xiyang; Zhu, Yuan; Tang, Sanyuan

• Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer

  Author: Zhang, Xiaoyi; Hong, Shasha; Yang, Jiang; Liu, Jingchun; Wang, Ying; Peng, Jiaxin; Wang, Haoyu; Hong, Li

• Hsa_circ_0007380 silencing restrains the growth and enhances radiosensitivity in esophagus cancer by miR-644a/Spindlin 1 axis

  Author: Yu, Weihui; Ning, Ke; Xiao, Jincheng; Bai, Qiwen; Guo, Chenyang

• Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade

  Author: Yu, Tao; Du, Hong; Sun, Changhai

英文介紹

Anti-cancer Drugs雜志英文介紹

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.